AR and acne: A recent example is the androgen receptor (AR)-PROTACGT20029 (undisclosed structure), which entered Phase I clinical trialin China for androgenetic alopecia and acne.46 However, when systemic administration is required, targeted deliverysystems may overcome limitations of poor selectivity and invivo pharmacokinetic (PK) profiles.